• Something wrong with this record ?

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

S. Verstovsek, R. Mesa, V. Gupta, D. Lavie, V. Dubruille, N. Cambier, U. Platzbecker, M. Hus, B. Xicoy, ST. Oh, JJ. Kiladjian, AM. Vannucchi, A. Gerds, M. Egyed, J. Mayer, T. Sacha, J. Kawashima, M. Morris, M. Huang, C. Harrison

. 2023 ; 7 (14) : 3582-3591. [pub] 2023Jul25

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23016829

Momelotinib is the first inhibitor of Janus kinase 1 (JAK1) and JAK2 shown to also inhibit activin A receptor type 1 (ACVR1), a key regulator of iron homeostasis, and has demonstrated improvements in splenomegaly, constitutional symptoms, and anemia in myelofibrosis (MF). This long-term analysis pooled data from 3 randomized phase 3 studies of momelotinib (MOMENTUM, SIMPLIFY-1, and SIMPLIFY-2), representing MF disease from early (JAK inhibitor-naive) to late (JAK inhibitor-experienced) stages. Patients in the control arms (danazol in MOMENTUM, ruxolitinib in SIMPLIFY-1, and best available therapy in SIMPLIFY-2) could cross over to receive momelotinib at the end of the 24-week randomized period, and all patients could continue momelotinib treatment after the completion of these studies via an extended access protocol (XAP). Across these studies, 725 patients with MF received momelotinib; 12% remained on therapy for ≥5 years, with a median treatment exposure of 11.3 months (range, 0.1-90.4 months). The most common nonhematologic treatment-emergent adverse event (AE) occurring in ≥20% of patients was diarrhea (any grade, 27% and grade ≥3, 3%). Any-grade thrombocytopenia, anemia, and neutropenia occurred in 25%, 23%, and 7% of patients, respectively. The most common reason for momelotinib discontinuation was thrombocytopenia (4% discontinuation rate). The incidence of AEs of clinical importance (eg, infections, malignant transformation, peripheral neuropathy, and hemorrhage) did not increase over time. This analysis of one of the largest randomized trial databases for a JAK inhibitor to date in MF demonstrated a consistent safety profile of momelotinib without long-term or cumulative toxicity. These trials were registered at www.clinicaltrials.gov as: MOMENTUM (#NCT04173494), SIMPLIFY-1 (#NCT01969838), SIMPLIFY-2 (#NCT02101268), and XAP (#NCT03441113).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016829
003      
CZ-PrNML
005      
20231026105521.0
007      
ta
008      
231013s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2022009311 $2 doi
035    __
$a (PubMed)37042865
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Verstovsek, Srdan $u The University of Texas MD Anderson Cancer Center, Houston, TX $1 https://orcid.org/0000000269128569
245    10
$a Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials / $c S. Verstovsek, R. Mesa, V. Gupta, D. Lavie, V. Dubruille, N. Cambier, U. Platzbecker, M. Hus, B. Xicoy, ST. Oh, JJ. Kiladjian, AM. Vannucchi, A. Gerds, M. Egyed, J. Mayer, T. Sacha, J. Kawashima, M. Morris, M. Huang, C. Harrison
520    9_
$a Momelotinib is the first inhibitor of Janus kinase 1 (JAK1) and JAK2 shown to also inhibit activin A receptor type 1 (ACVR1), a key regulator of iron homeostasis, and has demonstrated improvements in splenomegaly, constitutional symptoms, and anemia in myelofibrosis (MF). This long-term analysis pooled data from 3 randomized phase 3 studies of momelotinib (MOMENTUM, SIMPLIFY-1, and SIMPLIFY-2), representing MF disease from early (JAK inhibitor-naive) to late (JAK inhibitor-experienced) stages. Patients in the control arms (danazol in MOMENTUM, ruxolitinib in SIMPLIFY-1, and best available therapy in SIMPLIFY-2) could cross over to receive momelotinib at the end of the 24-week randomized period, and all patients could continue momelotinib treatment after the completion of these studies via an extended access protocol (XAP). Across these studies, 725 patients with MF received momelotinib; 12% remained on therapy for ≥5 years, with a median treatment exposure of 11.3 months (range, 0.1-90.4 months). The most common nonhematologic treatment-emergent adverse event (AE) occurring in ≥20% of patients was diarrhea (any grade, 27% and grade ≥3, 3%). Any-grade thrombocytopenia, anemia, and neutropenia occurred in 25%, 23%, and 7% of patients, respectively. The most common reason for momelotinib discontinuation was thrombocytopenia (4% discontinuation rate). The incidence of AEs of clinical importance (eg, infections, malignant transformation, peripheral neuropathy, and hemorrhage) did not increase over time. This analysis of one of the largest randomized trial databases for a JAK inhibitor to date in MF demonstrated a consistent safety profile of momelotinib without long-term or cumulative toxicity. These trials were registered at www.clinicaltrials.gov as: MOMENTUM (#NCT04173494), SIMPLIFY-1 (#NCT01969838), SIMPLIFY-2 (#NCT02101268), and XAP (#NCT03441113).
650    _2
$a lidé $7 D006801
650    12
$a primární myelofibróza $x diagnóza $7 D055728
650    12
$a inhibitory Janus kinas $x terapeutické užití $7 D000075242
650    _2
$a inhibitory proteinkinas $x škodlivé účinky $7 D047428
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    12
$a anemie $x chemicky indukované $7 D000740
650    12
$a trombocytopenie $x chemicky indukované $7 D013921
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mesa, Ruben $u UT Health San Antonio Cancer Center, San Antonio, TX
700    1_
$a Gupta, Vikas $u Princess Margaret Cancer Centre, Toronto, ON, Canada $1 https://orcid.org/0000000214198607
700    1_
$a Lavie, David $u Hadassah-Hebrew University Medical Center, Jerusalem, Israel
700    1_
$a Dubruille, Viviane $u Centre Hospitalier Universitaire de Nantes (CHU de Nantes), Nantes, France
700    1_
$a Cambier, Nathalie $u Service d'hématologie, Centre hospitalier régional universitaire de Lille (CHRU Lille), Lille, France
700    1_
$a Platzbecker, Uwe $u Clinic of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, Leipzig, Germany $1 https://orcid.org/0000000318633239
700    1_
$a Hus, Marek $u Uniwersytet Medyczny w Lublinie, Lublin, Poland
700    1_
$a Xicoy, Blanca $u Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain $1 https://orcid.org/0000000202951307
700    1_
$a Oh, Stephen T $u Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO $1 https://orcid.org/0000000285645400
700    1_
$a Kiladjian, Jean-Jacques $u Université de Paris, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM, Paris, France
700    1_
$a Vannucchi, Alessandro M $u Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, University of Florence, Careggi University Hospital, Florence, Italy
700    1_
$a Gerds, Aaron $u Cleveland Clinic, Cleveland, OH $1 https://orcid.org/0000000234221309
700    1_
$a Egyed, Miklos $u Teaching Hospital Mór Kaposi, Kaposvár, Hungary
700    1_
$a Mayer, Jiří $u Department of Internal Medicine, Haematology and Oncology, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Sacha, Tomasz $u Uniwersytet Jagielloński Collegium Medicum, Krakow, Poland $1 https://orcid.org/0000000272076595
700    1_
$a Kawashima, Jun $u Sierra Oncology, San Mateo, CA
700    1_
$a Morris, Marc $u Sierra Oncology, San Mateo, CA
700    1_
$a Huang, Mei $u Sierra Oncology, San Mateo, CA
700    1_
$a Harrison, Claire $u Guy's and St Thomas' National Health Services (NHS) Foundation Trust, London, United Kingdom
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 7, č. 14 (2023), s. 3582-3591
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37042865 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105515 $b ABA008
999    __
$a ok $b bmc $g 2000395 $s 1203191
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 7 $c 14 $d 3582-3591 $e 2023Jul25 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20231013

Find record

Citation metrics

Archiving options